CD28 and neoplasm: Similarly, we observed improved T cell activity upon anti-CD3/anti-CD28 stimulation in siB3 tumor–derived CD8+ T cells, which showed a markedly higher proliferative capacity than did those derived from siNC tumors (Figure 6F).